- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Auth. number :||EU/2/11/134|
|Active substance :||Meloxicam|
|ATC:||Anatomical main group: QM - Musculo-skeletal system|
Therapeutic subgroup: QM01 - Antiinflammatory and antirheumatic products
Pharmacological subgroup: QM01A - Antiinflammatory and antirheumatic products, non-steroids
Chemical subgroup: QM01AC - Oxicams
Chemical substance: QM01AC06 - meloxicam
(See WHO ATCvet Index)
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
For the relief of post-operative pain following dehorning in calves.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.
For the relief of post-operative pain associated with minor soft tissue such as castration.
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.
For the relief of pain associated with equine colic.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.
|Marketing Authorisation Holder:||Chanelle Pharmaceuticals Manufacturing Limited
Loughrea, Co. Galway, Ireland
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|13/12/2011||Centralised - Authorisation||EMEA/V/C/2497||(2011)9445 of 09/12/2011|
|20/08/2012||Centralised - Variation||EMEA/V/C/2497/X/2||(2012)5891 of 16/08/2012|
|12/11/2012||Centralised - Variation||EMEA/V/C/2497/X/1||(2012)8179 of 08/11/2012|
|14/02/2013||Centralised - Variation||EMEA/V/C/2497/WS/344||(2013)913 of 12/02/2013|
|27/09/2013||Centralised - Variation||EMEA/V/C/2497/IB/5|
|Updated with Decision(2014)6276 of 01/09/2014|
|03/09/2014||Centralised - Yearly update||(2014)6276 of 01/09/2014|
|04/12/2015||Centralised - Variation||EMEA/V/C/2497/X/9||(2015)8815 of 02/12/2015|
|08/09/2016||Centralised - Variation||EMEA/V/C/2497/WS/933|
|Updated with Decision(2016)7293 of 09/11/2016|
|28/10/2016||Centralised - Variation||EMEA/V/C/2497/IB/13|
|Updated with Decision(2017)7270 of 24/10/2017|
|11/11/2016||Centralised - Renewal||EMEA/V/C/2497/R/11||(2016)7293 of 09/11/2016|
|26/10/2017||Centralised - Yearly update||(2017)7270 of 24/10/2017|